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ABSTRACT
Introduction: Advances in the treatment of
metastatic melanoma have been achieved in
recent years: immunotherapies and targeted
therapies have demonstrated survival benefits
over older agents such as
granulocyte-macrophage colony-stimulating
factor (GM-CSF), dacarbazine, and
glycoprotein peptide vaccine (gp100) in
pivotal phase 3 trials. It is important to
compare therapies to guide the treatment
decision-making process, and establishing the
relationship between older agents can
strengthen the networks of evidence for newer
therapies. We report the outcome of an indirect
comparison of GM-CSF, dacarbazine, and gp100
in metastatic melanoma through meta-analysis
of absolute treatment effect.
Methods: A systematic literature review
identified trials for inclusion in the
meta-analysis. A valid network meta-analysis
was not feasible: treatment-specific
meta-analysis was conducted. A published
algorithm was used to adjust overall survival
estimates fromtrialsofGM-CSF,dacarbazine, and
gp100 for heterogeneity in baseline prognostic
factors. Survival estimates were compared in
three patient groups: stage IIIB–IV M1c,
stage IIIB–IV M1a, and stage IV M1b/c.
Results: One trial of GM-CSF, four of
dacarbazine, and one of gp100 were included
in the analysis. After adjusting for differences in
baseline prognostic factors, median overall
survival (OS) in all patient groups was longer
for those receiving GM-CSF than for those
receiving dacarbazine or gp100. The observed
survival over time for GM-CSF was similar to the
adjusted survival for dacarbazine and greater
than for gp100 in all patient groups.
Conclusion: The relative treatment effect of
GM-CSF, dacarbazine, and gp100 has been
reliably estimated by adjusting for differences
in baseline prognostic factors. Results suggest
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that OS with GM-CSF is at least as good as with
dacarbazine and greater than with gp100. Given
the role of these agents as controls in phase 3
trials of new immunotherapies and targeted
agents, these results can be used to
contextualize the efficacy of newer therapies.
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Metastatic melanoma is a serious disease with a
poor survival outcome; the 5-year survival rate
for patients with distant metastases at diagnosis
is 15–20% [1, 2]. Until recently, therapies for
unresectable metastatic melanoma had no
confirmed survival benefit and the aim of
treatment was palliation [3]. However, the
number of treatment options has increased
rapidly since 2011. Immunotherapies and
targeted agents have demonstrated survival
benefits in randomized controlled phase 3
trials and are now recommended for first- and
second-line treatment of metastatic melanoma
[4, 5]. The choice of treatment may be guided by
the patient’s BRAF mutation status: the BRAF
kinase inhibitors vemurafenib and dabrafenib
are used to treat mutated-BRAF disease, which
accounts for approximately 40–50% of
melanoma cases, whereas immunotherapies
such as ipilimumab, pembrolizumab, and
nivolumab, and the oncolytic virus therapy
talimogene laherparepvec, can be used
regardless of BRAF mutation status [4–6].
Many of these new treatment options were
evaluated in phase 3 trials against older agents.
Each new treatment was compared with the
agent or regimen considered appropriate for
that trial setting at the time when the trials were
designed, which led to the use of a wide range of
control agents in pivotal trials. For example,
ipilimumab was compared with glycoprotein
peptide vaccine (gp100) in previously treated
patients [7] and with dacarbazine in the
first-line setting [8]. Dacarbazine was also the
control agent in trials of vemurafenib and
dabrafenib monotherapy [9, 10], whereas
granulocyte-macrophage colony-stimulating
factor (GM-CSF) was the control agent in the
pivotal trial of talimogene laherparepvec [11].
As the treatment landscape continues to
develop, it is important to compare currently
used therapies to guide the treatment
decision-making process. However, there are
challenges in estimating the relative treatment
effects for these newer therapies, at least in part
because they were compared to older agents in
phase 3 trials and the relative efficacy of these
older agents has never been established.
Systematic evaluations of new treatment
options (health technology assessments [12])
have not discounted the possibility of equipoise
between gp100 and placebo; however, there is
no precedent for making the same assumption
for dacarbazine. By better understanding the
relative efficacy of older agents, it may be
possible to strengthen the networks of
evidence and indirect treatment comparisons
of the newer therapies.
Here we report the outcome of an indirect
treatment comparison of survival with GM-CSF,
dacarbazine, and gp100 in phase 3 randomized
controlled trials in metastatic melanoma. The
indirect treatment comparison took the form of
a treatment-specific meta-analysis of absolute
treatment effect, with adjustment for
heterogeneity in prognostic factors for
survival. Given that survival rates vary
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according to stage of disease [13], we also have
compared relative survival with these agents in
three populations: stage IIIB–IV M1c
melanoma, that is all patients in the trials;
stage IIIB–IV M1a melanoma (early metastatic
melanoma), that is patients without bone,
brain, lung, or other visceral metastases; and
stage IV M1b/c melanoma (late metastatic




A systematic literature review was carried out to
identify relevant trials relating to treatments for
melanoma; the methodology has been
described in full elsewhere [14]. The systematic
review followed Cochrane and Preferred
Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines. Briefly,
clinical trials published between January 1990
and September 2015 that evaluated the efficacy
and safety of treatments for metastatic
melanoma were identified from searches of the
following databases: MEDLINE, including
MEDLINE In-Process Citations and Daily
Update (PubMed; OvidSP); Embase (OvidSP);
and the Cochrane Library, including the
Cochrane Database of Systematic Reviews
(CDSR), Database of Abstracts of Reviews of
Effects (DARE), Cochrane Central Register of
Controlled Trials (CENTRAL), Health
Technology Assessment (HTA) Database, and
the NHS Economic Evaluation Database
(NHSEED). To identify relevant studies
presented at conferences, the following
meeting proceedings were also searched:
American Society of Clinical Oncology
(ASCO), European Association of Dermato
Oncology (EADO), European Cancer Congress
(ECC), European Society for Medical Oncology
(ESMO), and International Society for
Pharmacoeconomics and Outcomes Research
(ISPOR; European and international
conferences).
The trials identified in the review were
assessed against pre-specified inclusion and
exclusion criteria; trials that met these criteria
and that investigated the agents of interest were
then assessed for bias and study quality using
the Grades of Recommendation, Assessment,
Development and Evaluation (GRADE) criteria
[15].
Establishing the Feasibility of a Valid
Network Meta-Analysis
The feasibility of conducting a valid network
meta-analysis of GM-CSF, dacarbazine, and
gp100 was assessed using a process developed
and published by Cope and colleagues [16]. The
network of evidence for previously untreated or
treated melanoma is shown in Fig. 1, including
both current treatments and the control agents
included in the trials. The network had few
trials and generally one trial per connection;
aside from dacarbazine, each of the treatments
of interest occurred in only a single trial. There
were no head-to-head data for the treatments of
interest and patient characteristics (e.g., stage of
disease, previous treatment) differed between
trial populations meaning that a valid network
of evidence could not be established [17].
Indirect Treatment Comparisons
The use of treatment-specific meta-analysis of
absolute treatment effect as an alternative
approach to indirect treatment comparison
has been previously reported when a valid
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network of evidence could not be established
[14]. We used the same approach here, which
involved analysis of survival data for GM-CSF,
dacarbazine, and gp100 from metastatic
melanoma trials in which these agents were
studied as monotherapy.
Survival outcomes were adjusted for
heterogeneity in prognostic factors to permit a
valid comparison between agents. Adjustments
were based on a predictive model for survival
developed by Korn and colleagues [18]; a
modified version of the model has been
accepted by the UK National Institute for
Health and Care Excellence (NICE) [19]. The
modified Korn model produces a hazard ratio
(HR) based on five prognostic factors for
survival: sex, Eastern Cooperative Oncology
Group performance status, presence of visceral
metastases, presence of brain metastases, and
lactate dehydrogenase (LDH) level. Survival was
adjusted using the HR as the modifier, thereby
reflecting the impact of the difference in patient
characteristics between trial arms for each
agent.
GM-CSF was considered the reference agent
for the indirect treatment comparison since
this permitted additional analyses of survival
rates according to stage of disease (early and
late metastatic melanoma). To test the
robustness of the indirect treatment
comparison, survival outcomes were also
analyzed using dacarbazine as the reference,
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Fig. 1 Network of evidence for previously untreated or
treated melanoma. a Trial ongoing but data are reported;
b Non-standard dose, administration, or setting; c Previously
treated patients; d NCT identiﬁer not available, data
published (Ravaud et al. 2001). GM-CSF
granulocyte-macrophage colony-stimulating factor, gp100
glycoprotein peptide vaccine, T-VEC talimogene
laherparepvec
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Survival outcomes were analyzed separately
for each comparator. Where survival outcomes
for a particular comparator were available from
more than one trial, estimates of overall survival
(OS) from each trial were adjusted separately
using the modified Korn model and then
pooled using the Mantel–Haenszel method
[20, 21]. A detailed description of the
application of the modified Korn model and
Mantel–Haenszel method is published
elsewhere [14].
Survival outcomes with GM-CSF were
available according to stage of disease—that is,
for patients without bone, brain, lung, or other
visceral metastases (stage IIIB–IV M1a) and
patients with visceral metastases (stage IV
M1b/c). These data were not available for
dacarbazine and gp100, so adjustment factors
for dacarbazine and gp100 did not include this
specificity.
For the analyses using dacarbazine as the
reference agent, adjusted survival outcomes
with GM-CSF and gp100 were determined
relative to dacarbazine for all patients
(stage IIIB–IV M1c disease). As survival
outcomes with dacarbazine were not available
according to stage of disease, it was not possible
to conduct the indirect comparison of
treatments on the subgroups of patients with
early or late metastatic melanoma using
dacarbazine as the reference agent.
Extracting Survival Data for Analysis
DigitizeIt version 2.0.3 software was used to
extract and digitize Kaplan–Meier curves [22].
This provided survival estimates at consecutive
half-month intervals for the relevant arm of
each trial. Median survival estimates from the
digitized datasets were compared with the
published median survival estimates to
establish the quality of the outputs.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




Figure 2 shows the PRISMA flow diagram
illustrating the identification of studies in the
systematic review. Trials that had evaluated
GM-CSF, dacarbazine, or gp100 as control
agents were identified for inclusion in the
meta-analysis on the basis of the following
criteria: they had to be randomized phase 3
trials published from 2010 onwards, OS curves
had to be reported, as did patient baseline
Records idenﬁed from databases
(MEDLINE, Embase, and Cochrane CENTRAL 
Registry of Controlled Clinical Trials)
(n =  60)
39 studies excluded as they 
did not evaluate relevant 
intervenons/comparators 
Studies evaluang GM-CSF, 
dacarbazine, or gp100
(n = 21)
Studies included for the 
meta-analysis (n = 6)
15 studies excluded for 
other reasons: 
• 9 studies were not 
Phase 3 randomized 
controlled trials
• 5 studies did not report 
key variables required 
for indirect treatment 
comparison
• 1 study did not report 
mature overall survival 
data
Fig. 2 PRISMA ﬂow diagram for the systematic review.
GM-CSF granulocyte-macrophage colony-stimulating factor,
gp100 glycoprotein 100, PRISMA Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
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characteristics relevant to the modified Korn
model.
Trials Included in the Indirect Treatment
Comparison
In total, six trials were identified for inclusion in
the indirect treatment comparison: one trial
with GM-CSF, four trials with dacarbazine, and
one trial with gp100. All of the trials were
designed to meet regulatory requirements and
were therefore considered of sufficient quality
to include in the analyses; it was not considered
necessary to use formal assessments of potential
bias (e.g., using GRADE criteria) to further refine
the list of trials included in the analyses.
The baseline characteristics of patients
enrolled in these trials are listed in Table 1.
Sex, a prognostic factor for survival, was
generally balanced across trials but there were
important differences in some other prognostic
factors: patients enrolled in the GM-CSF trial
seemed to have a better prognosis than those in
the dacarbazine trials and the gp100 trial; for
example, a higher percentage of patients in the
GM-CSF trial had stage IIIB–IV M1a disease and
a higher percentage had normal LDH levels.
The heterogeneity in patient baseline
characteristics across the trials confirmed the
need for adjustment before comparing the
survival outcomes for the three agents,
although heterogeneity in outcomes could not
be assessed quantitatively because of the small
number of trials and the variation in sample
sizes.
The modified Korn model was applied to
adjust for differences in the five baseline
prognostic factors, and an HR modifier was
calculated for each trial. Adjustment factors
were then determined from the ratio of the HR
modifiers for GM-CSF (or dacarbazine) and the
comparator agents.
Relative Survival in all Patients
(Stage IIIB–IV M1c)
GM-CSF as the Reference Agent
Table 2 lists the adjustment factors applied to
determine the relative survival effect of
dacarbazine and gp100 compared with
GM-CSF in all patients (stage IIIB–IV M1c
disease). All the adjustment factors are less
than 1, reflecting the poorer survival prognosis
for patients in the dacarbazine trials and gp100
trial compared with those in the GM-CSF trial.
The observed median OS estimate for
GM-CSF and the unadjusted and adjusted
median OS estimates for dacarbazine and
gp100 in all patients are presented in Table 3.
For both dacarbazine and gp100, adjustment for
patient baseline characteristics substantially
increased adjusted median OS compared with
the unadjusted estimates. Again, this reflects
the poorer original survival prognosis driven by
the patient characteristics in the dacarbazine
trials and the gp100 trial. Median OS with
GM-CSF was estimated to be longer than with
dacarbazine or gp100, even after adjusting for
heterogeneity in patient baseline
characteristics.
The observed OS curve for GM-CSF and
unadjusted OS curves for dacarbazine and
gp100 are shown in Fig. 3. Adjustment for
differences in baseline prognostic factors
improved OS for both dacarbazine (Fig. 4) and
gp100 (Fig. 5) at each time point along the
curve. The observed OS for GM-CSF was greater
than the unadjusted OS for dacarbazine and
gp100 at each time point. The observed OS for
GM-CSF was also greater than the adjusted OS
for dacarbazine at every time point (Fig. 4);
however, the observed OS for GM-CSF tracked
close to or just below the upper bound of the
95% confidence interval (CI) of the adjusted OS
curve for dacarbazine, which suggested that the
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survival estimates for the two agents might be
similar. When comparing the observed OS for
GM-CSF with the adjusted OS for gp100 (Fig. 5),
the observed OS for GM-CSF tracked above the
upper bound 95% CI of the adjusted OS curve
for gp100 at every time point, even though
differences in the trial populations that might
affect survival outcomes had been accounted
for, suggesting greater efficacy for GM-CSF
throughout the survival curve.
Dacarbazine as the Reference Agent
Table 4 lists the adjustment factors applied to
determine the relative survival effect of GM-CSF
and gp100 compared with dacarbazine in all
patients (stage IIIB–IV M1c disease). Similarly to
the original analysis, median OS with GM-CSF
was longer than with dacarbazine and gp100,
even after adjusting for heterogeneity in patient
baseline characteristics (Table 5).
Although adjustment for differences in
baseline prognostic factors reduced OS for
GM-CSF at each time point compared with the
observed data, the adjusted GM-CSF curve still
dominated the observed OS curve for
dacarbazine (Fig. 6). Moreover, the lower 95%
CI for GM-CSF tracked above or on the observed
OS curve for dacarbazine, suggesting that the
survival estimates may be similar and
supporting the outcome of the original
analysis. The adjusted OS for gp100 tracked
below the observed OS for dacarbazine but with
some overlap with the upper 95% CI (Fig. 7),
again suggesting that the survival estimates for
the two treatments are similar.
Relative Survival in Patients with Early
Metastatic Melanoma (Stage IIIB–IV M1a)
Stage IIIB–IV M1a disease, in which bone, brain,
lung, and other visceral metastases are absent,
can be considered an early stage of metastatic
melanoma. Table 6 lists the adjustment factors
applied to determine the relative survival effect
of dacarbazine and gp100 compared with
GM-CSF in these patients. As stated previously,
the adjustment factors for GM-CSF were specific
to the stage of disease (i.e., to
stage IIIB–IV M1a), but those for dacarbazine
and gp100 were not.
Table 2 Overall survival curve adjustment: HR and adjustment factor for all patients (stage IIIB–IV M1c)
Trial (drug, patient population) HR for comparators HR for GM-CSF Adjustment factor
CA184-024 (dacarbazine, previously untreated) [8] 0.32 0.22 0.69
BRIM-3 (dacarbazine, previously untreated) [10] 0.32 0.22 0.69
BREAK-3 (dacarbazine, previously untreated) [9] 0.29 0.22 0.76
Daponte (dacarbazine, previously untreated) [25] 0.39 0.22 0.57
MDX010-20 (gp100, previously treated) [7] 0.34 0.22 0.65
GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, HR hazard ratio
Table 3 Median overall survival in months: all patients
(stage IIIB–IV M1c)






factor, gp100 glycoprotein 100, NA not applicable
a Observed median overall survival
b Based on pooled analysis of four dacarbazine curves
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The absence of brain or visceral metastases is
recognized as a positive prognostic factor for OS
and so, as would be expected, adjustment
factors for this group were lower than those
for the corresponding total patient populations
across all trials, resulting in a greater impact on
survival outcomes.
The observed median OS estimate for
GM-CSF and the unadjusted and adjusted
median OS estimates for dacarbazine and
gp100 are shown in Table 7. For both
dacarbazine and gp100, the adjusted median
OS for this population was longer than for the


















Observed OS for GM-CSF
Upper 95% CI of adjusted OS for dacarbazine
Adjusted OS for dacarbazine
Lower 95% CI of adjusted OS for dacarbazine
Unadjusted OS for dacarbazine
Fig. 4 Unadjusted and adjusted Kaplan–Meier OS curves
for dacarbazine vs observed OS curve for GM-CSF, all
patients (stage IIIB–IV M1c). CI conﬁdence interval,
GM-CSF granulocyte-macrophage colony-stimulating


















Observed OS for GM-CSF
Unadjusted OS for dacarbazine
Unadjusted OS for gp100
Fig. 3 Unadjusted Kaplan–Meier OS curves for
dacarbazine and gp100 vs observed OS curve for GM-CSF,
all patients (stage IIIB–IV M1c). GM-CSF
granulocyte-macrophage colony-stimulating factor, gp100
glycoprotein 100, OS overall survival
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expected given the better survival prognosis.
Median OS with GM-CSF was longer than with
dacarbazine or gp100 even after adjusting for
heterogeneity in patient baseline
characteristics.
As in the overall patient population, the
observed OS for GM-CSF was greater than the
adjusted OS for both dacarbazine and gp100
at every time point (Fig. 8). Again, the
observed OS for GM-CSF tracked close to or
on the upper bound 95% CI of the adjusted
OS curve for dacarbazine and above the upper
bound 95% CI of the adjusted OS curve for
gp100.
Relative Survival in Patients with Late
Metastatic Melanoma (Stage IV M1b/c)
Stage IV M1b/c disease, where visceral
metastases are present, can be considered a
late stage of metastatic melanoma. Table 8 lists
the adjustment factors applied to determine the
relative survival effect of dacarbazine and gp100
compared with GM-CSF in this population. The
adjustment factors for this group were greater
than those for the corresponding total patient
populations across all trials, reflecting the
poorer survival prognosis as determined by the


















Observed OS for GM-CSF
Upper 95% CI of adjusted OS for gp100
Adjusted OS for gp100
Lower 95% CI of adjusted OS for gp100
Unadjusted OS for gp100
Fig. 5 Unadjusted and adjusted Kaplan–Meier OS curves
for gp100 vs observed OS curve for GM-CSF, all patients
(stage IIIB–IV M1c). CI conﬁdence interval, GM-CSF
granulocyte-macrophage colony-stimulating factor, gp100
glycoprotein 100, OS overall survival
Table 4 Overall survival curve adjustment to dacarbazine reference: HR and adjustment factor for all patients
(stage IIIB–IV M1c)






OPTiM (GM-CSF, previously treated and untreated)
[11]
0.22 0.32 1.46
MDX010-20 (gp100, previously treated) [7] 0.34 0.32 0.95
GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, HR hazard ratio
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For dacarbazine and gp100, the unadjusted
and adjusted median OS estimates for these
patients are shown in Table 9, alongside the
observed median OS estimate for GM-CSF. The
adjusted median OS for each agent was shorter
for these patients than for the overall patient
population, again reflecting the poorer survival
prognosis. Median OS with GM-CSF was longer
than with dacarbazine or gp100, even after
adjusting for heterogeneity in patient baseline
characteristics.
The observed OS for GM-CSF was similar to
the adjusted OS for dacarbazine, tracking on
or close to the OS curve for dacarbazine at
every time point (Fig. 9). The observed OS for
GM-CSF was greater than the adjusted OS for
gp100 at every time point, and tracked above
the upper bound 95% CI of the gp100 OS
curve.
DISCUSSION
The treatment landscape for metastatic
melanoma has evolved rapidly in recent
years. Evidence of significant survival
benefits from randomized controlled phase 3
trials means that immunotherapies and
targeted agents are now treatment options
for a patient population that historically has
been considered difficult to treat [4, 5, 23].
There are challenges in estimating the relative
treatment effects of new therapies, however,
because they were compared to different older
agents in pivotal phase 3 trials and the
relative efficacy of these older agents has
never been established. By better
understanding the relative efficacy of older


















Unadjusted OS for GM-CSF
Upper 95% CI for adjusted OS for GM-CSF
Adjusted OS for GM-CSF
Lower 95% CI for adjusted OS for GM-CSF
Observed OS for dacarbazine
Fig. 6 Unadjusted and adjusted Kaplan–Meier OS curves
for GM-CSF vs observed OS curve for dacarbazine, all
patients (stage IIIB–IV M1c). CI conﬁdence interval,
GM-CSF granulocyte-macrophage colony-stimulating
factor, OS overall survival
Table 5 Median overall survival in months: all patients
(stage IIIB–IV M1c)






factor, gp100 glycoprotein 100, NA not applicable
a Observed median overall survival (based on pooled
analysis of four dacarbazine curves)
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networks of evidence and indirect treatment
comparisons of the newer therapies.
In this indirect treatment comparison, the
choice of agents for the analysis was driven by
the choice of control agents in the pivotal trials
of newer immunotherapies and targeted agents.
GM-CSF was the control in the pivotal trial of
talimogene laherparepvec [11], gp100 in the
registration trial of ipilimumab [7], and
dacarbazine in the trials of vemurafenib and
dabrafenib monotherapies in the first-line
setting [9, 10] and also in another trial of
ipilimumab [8]. Dacarbazine is the most
commonly used older systemic chemotherapy
to treat metastatic melanoma. Guidelines from
the European Society of Medical Oncology
consider dacarbazine or temozolomide an
option for the treatment of stage IV metastatic
disease in situations where a clinical trial,
immunotherapy, or targeted therapy is not
available [4].
The current analysis showed that median OS
was longer in patients who received GM-CSF
than in those who received dacarbazine, even
after adjusting for differences in baseline


















Observed OS for dacarbazine
Upper 95% CI for adjusted OS for gp100
Adjusted OS for gp100
Lower 95% CI for adjusted OS for gp100
Unadjusted OS for gp100
Fig. 7 Unadjusted and adjusted Kaplan–Meier OS curves for gp100 vs observed OS curve for dacarbazine, all patients
(stage IIIB–IV M1c). CI conﬁdence interval, gp100 glycoprotein 100, OS overall survival
Table 6 Overall survival curve adjustment: HR and adjustment factor for patients with early metastatic melanoma
(stage IIIB–IV M1a)
Trial (drug, patient population) HR for comparators HR for GM-CSF Adjustment factor
CA184-024 (dacarbazine, previously untreated) [8] 0.32 0.20 0.64
BRIM-3 (dacarbazine, previously untreated) [10] 0.32 0.20 0.64
BREAK-3 (dacarbazine, previously untreated) [9] 0.29 0.20 0.70
Daponte (dacarbazine, previously untreated) [25] 0.39 0.20 0.52
MDX010-20 (gp100, previously treated) [7] 0.34 0.20 0.60
GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, HR hazard ratio
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consistently observed in early-stage disease
(without bone, brain, lung, or other visceral
metastases) and in late-stage disease (with
visceral metastases). The survival estimates
over time for GM-CSF were similar to the
adjusted survival estimates for dacarbazine;
this was also the case when dacarbazine was
considered the reference agent. Median OS was
longer in patients who received GM-CSF than in
those who received gp100 after adjusting for
differences in baseline prognostic factors for
survival. Again, this was consistently observed
in early and late metastatic melanoma. Survival
rates for GM-CSF were higher than those for
gp100 at each time point evaluated, tracking
above the upper bound 95% CI of the adjusted
gp100 OS curve. This suggests that GM-CSF has
greater efficacy than gp100, throughout the
distribution of survival.
This analysis has some limitations that are
common already to previous analyses of
treatment for melanoma. There were only a
small number of qualifying trials and the
adjustments made to the survival curves were
based on a number of observed prognostic
factors. It is possible that other unobserved
factors also influenced the trial results; however,
the factors included were previously identified
on the basis of data from a large number of
metastatic melanoma trials [18, 19] and have
been used multiple times in adjustments for
differences between studies in melanoma



















Observed OS for GM-CSF
Upper 95% CI of adjusted OS for dacarbazine
Adjusted OS for dacarbazine
Lower 95% CI of adjusted OS for dacarbazine
Upper 95% CI of adjusted OS for gp100
Adjusted OS for gp100
Lower 95% CI of adjusted OS for gp100
Fig. 8 Adjusted Kaplan–Meier OS curves for dacarbazine
and gp100 vs observed OS curve for GM-CSF, patients
with early metastatic melanoma (stage IIIB–IV M1a). CI
conﬁdence interval, GM-CSF granulocyte-macrophage
colony-stimulating factor, gp100 glycoprotein 100, OS
overall survival
Table 7 Median overall survival in months: patients with
early metastatic melanoma (stage IIIB–IV M1a)






factor, gp100 glycoprotein 100, NA not applicable, NR
not reported, however, the adjusted data exist because, for
gp100 and dacarbazine, the entire stage IIIB–IV data were
used
a Observed median overall survival
b Based on pooled analysis of four dacarbazine curves
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The network of evidence was such that it
could not establish similarity or consistency in
studies or treatment effects. This was not
surprising, as trials of these agents in
melanoma are sporadic, spanning back to the
year 2000, and include various treatment
settings. In the absence of such a network,
adjustment for baseline prognostic factors was
undertaken using the modified Korn model;
however, there still could be uncertainty. For
example, the single study that addressed the
efficacy of GM-CSF was the OPTiM trial, which
had some identifiably different patient
characteristics, as well as better-specified data
on disease stage (more patients without visceral
disease were included in the trial). Some of the
differences in survival, therefore, could be
ascribed to patient characteristics. However,
this was mitigated to a degree by the inclusion
of visceral disease in the modified Korn model,
and further mitigated by separate analyses of
disease with and without bone, brain, lung, or
other visceral diseases. The consistent findings
from all patients (stage IIIB–IV M1c), patients
with early metastatic melanoma (stage IIIB–IV
M1a), and patients with late metastatic
melanoma (stage IV M1b/c) increase the
confidence in the results.
To our knowledge, this is the first study to
compare the relative treatment effects of the
control agents used in phase 3 trials of newer
immunotherapies and targeted agents for
metastatic melanoma. By adjusting for
observed differences in patient characteristics
across the trials, we have reliably estimated the
relative survival associated with each agent.
Findings from this study may help strengthen
the networks of evidence in metastatic
melanoma, and help future studies establish
the relative value of treatments for metastatic
melanoma.
Table 8 Overall survival curve adjustment: HR and adjustment factor for patients with late metastatic melanoma
(stage IV M1b/c)
Trial (drug, patient population) HR for comparators HR for GM-CSF Adjustment factor
CA184-024 (dacarbazine, previously untreated) [8] 0.32 0.25 0.79
BRIM-3 (dacarbazine, previously untreated) [10] 0.32 0.25 0.79
BREAK-3 (dacarbazine, previously untreated) [9] 0.29 0.25 0.86
Daponte (dacarbazine, previously untreated) [25] 0.39 0.25 0.65
MDX010-20 (gp100, previously treated) [7] 0.34 0.25 0.74
GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, HR hazard ratio
Table 9 Median overall survival in months: patients with
late metastatic melanoma (stage IV M1b/c)






factor, gp100 glycoprotein 100, NA not applicable, NR
not reported; however, the adjusted data exist because, for
gp100 and dacarbazine, the entire stage IIIB–IV data were
used
a Observed median overall survival, b Based on pooled
analysis of four dacarbazine curves
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CONCLUSIONS
In this indirect treatment comparison, using
data from randomized controlled phase 3 trials
in metastatic melanoma, the relative treatment
effect of GM-CSF, dacarbazine, and gp100 has
been reliably estimated by adjusting for
differences in prognostic factors for survival
between patient populations. After adjustment,
GM-CSF had survival estimates that were at
least as good as those for dacarbazine over time,
a finding supported by sensitivity analysis with
dacarbazine as the reference agent. Compared
with gp100, GM-CSF had higher rates of
survival at each time point and longer median
OS, suggesting greater efficacy throughout the
distribution of survival. Importantly,
comparing relative treatment effects according
to stage of disease consistently yielded the same
pattern. Given the role of these agents as
controls in pivotal phase 3 trials of new
immunotherapies and targeted agents, the
results of this analysis can be used to
contextualize the efficacy of these new
therapies.
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